Cedars-Sinai Cancer | Strategic Alliance Partners

Cedars-Sinai Cancer in Los Angeles serves one of the most diverse regions globally. Ranked No. 7 for cancer by U.S. News & World Report 2020-2021, the center’s clinicians are committed to providing compassionate, state-of-the-art care, while its scientists are carrying out the latest translational research and groundbreaking advances. The cancer enterprise includes the Samuel Oschin Comprehensive Cancer Institute, The Angeles Clinic and Research Institute, Tower Hematology Oncology Medical Group, Torrance Memorial Hunt Cancer Center and Cedars-Sinai Tarzana.

Latest from Cedars-Sinai Cancer

Broader Testing Options Pave the Way for Increasingly Tailored Lung Cancer Treatments

May 17, 2022

Article

The efficacy of targeted therapies for patients with lung cancer relies on detailed testing approaches found only in DNA- and RNA-based sequencing assays to identify specific mutations.

State of Science Summit- Precision Medicine - Lung Cancer: Chaired by Karen L. Reckamp, MD, MS

April 21, 2022

Article

State of Science Summit- Precision Medicine - Lung Cancer: Chaired by Karen L. Reckamp, MD, MS

Blood & Marrow Transplant Outcomes Exceed Expectations

February 01, 2022

Article

The Cedars-Sinai Cancer Blood & Marrow Transplant Program’s one-year patient survival rate exceeded expectations compared to transplant centers in the U.S. whose similar patients underwent allogeneic transplants.

Dr. Hamid on the Differences in Evaluation Criteria for TIL Therapy in Melanoma

January 12, 2022

Video

Omid Hamid, MD, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes therapy in melanoma.

Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

January 12, 2022

Video

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

November 22, 2021

Video

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Pancreatic Cancer Incidence Rises, Notably Among Younger Women

October 31, 2021

Article

Incidence of pancreatic cancer incidence rose overall from 2000 to 2018, with a significant increase in women younger than 55 years, especially those aged 15 to 35 years.

Cedars-Sinai Researchers Develop New Melanoma Staging System

September 23, 2021

Article

Cedars-Sinai Cancer researchers have created a new system for classifying melanoma when the disease has spread to the lymph nodes.

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

August 13, 2021

Video

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Dr. Basho on the Emergence of Bispecific Antibodies in HER2+ Breast Cancer

August 13, 2021

Video

Reva K. Basho, MD, discusses the emergence of bispecific antibodies in HER2-positive breast cancer.

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

August 01, 2021

Video

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31, 2021

Article

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

Dr. Basho on the Evolution of Therapeutic Sequencing in HER2+ Breast Cancer

July 28, 2021

Video

Reva K. Basho, MD, discusses the evolution of therapeutic sequencing in HER2-positive breast cancer.

Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

July 22, 2021

Video

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Survival Advantages in Metastatic Breast Cancer Move the Needle Toward Curative-Intent Strategies

July 08, 2021

Article

Heather L. McArthur, MD, MPH, discusses key advances in breast cancer regarding CDK4/6 inhibitors, PI3K inhibitors, and subcutaneous formulations of standard treatments.

Institutional Perspectives in Cancer- Breast: Chaired by Heather McArthur, MD, MPH

June 23, 2021

Video

Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric Cancer

June 14, 2021

Video

Katelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.

Role of Adjuvant Chemoradiation Under Study in Gastric Cancer

May 16, 2021

Article

Katelyn M. Atkins, MD, PhD, examines the evolving role of radiotherapy in the treatment of patients with gastric cancer, the subgroups who might derive the most benefit from this approach, and ongoing research efforts that are seeking to address remaining questions with this modality.

Gong Gives Perspective on Sequencing Challenges Faced in Advanced HCC

May 14, 2021

Article

Jun Gong, MD, discusses the impact of the IMbrave150 trial on the advanced HCC treatment paradigm and challenges faced with sequencing.

The Future of Cancer Immunotherapy Lies in Combinational Approaches

May 06, 2021

Article

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.